Brief: Hungary's Richter CEO Sees Pharma Revenues Growing Around 10% In 2025
28/02/2025 08:32
Feb 28 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU: HUNGARY RICHTER CEO SAYS ALL FOUR BUSINESS UNITS ACHIEVED DOUBLE-DIGIT SALES GROWTH IN HUF TERMS IN 2024 HUNGARY'S RICHTER CEO EXPECTS PHARMA REVENUES TO GROW AROUND 10% IN 2025 HUNGARY'S RICHTER CEO SAYS WE CAN RELY ON CARIPRAZINE LESS AND LESS, EXPECTS OTHER SEGMENTS TO GROW FASTER THAN CARIPRAZINE SALES HUNGARY'S RICHTER CEO GABOR ORBAN EXPECTS NEUROPSYCHIATRY SEGMENT TO GROW AT 7%-8% IN 2025 Further company coverage: GDRB.BU (Warsaw Newsroom:) ((warsaw.newsroom@thomsonreuters.com; +48 22 6539700; Reuters Messaging: warsaw.newsroom.reuters.com@thomsonreuters.net))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab